Press release


Press release

2022, Bucharest

Bucharest, November 3, 2022

FutureLife announces that it has successfully completed negotiations for a partnership with CytoGenomic Medical Laboratory, a Romania’s leading genetic laboratory.

Dr. Danae Stambouli, founder of CytoGenomic, will remain a significant shareholder and scientific director driving the company’s growth plans and heading operations.

Together, FutureLife and CytoGenomic will provide the Romanian market with innovative technologies and the latest genetic analysis and tests, extending the company’s services to an even wider number of doctors and patients.

“This partnership creates added value for the Romanian market bringing advanced scientific opportunities to the field of reproductive genetic and preventive medicine. The decision to expand our extensive portfolio of products with the most advanced and innovative tests will raise awareness of the benefits of genetics for public health,” said Dr. Danae Stambouli, CytoGenomic Founder and Scientific Director.

“Since the establishment of CytoGenomic in 2008, we have focused on providing Romanian society with the very best up-to-date services in genetic diagnosis. Consistent with our vision, we are proud and pleased to be expanding the services and security we offer our partners and patients through our partnership with Future Life.”

Matej Stejskal, CEO FutureLife Group, said: „We are very excited about our partnership with Dr. Danae Stambouli and Cytogenomics. Advanced genetic testing helps achieve higher pregnancy and birth rates. FutureLife continues to partner with like-minded professionals who are able to help us grow our business further and bring excellence to our operations.”

CytoGenomic Medical Laboratory offers a wide range of services, integrating the latest technologies and scientific developments for the benefit of the community. To achieve this it collaborates with over 45 clinics and hospitals.

Over the last decade, the company has expanded rapidly and is now providing more than 15,000 genetic analyses and tests annually. CytoGenomic’s latest innovation is the new Linea Vita genetic test, the first carrier screening test developed in Romania.

Linea Vita analyses 150 genes responsible for 217 genetic disorders. With the launch of the ground-breaking test, CytoGenomic has made a fundamental contribution to preventive medicine in Romania and South Eastern Europe.